ObesityNCT02828228
Vitamin D Supplementation in Vitamin D Deficient Obese Children During Weight-loss Program
A study testing Vitamin D 1200 IU in people with Obesity, run by University Clinical Centre, Gdansk at 1 site in Poland.
Trial summary
1. Analyze the influence of vitamin D supplementation in obese children during weight-loss program on BMI, body composition and bone mineral density. 2. Analyze the influence of vitamin D supplementation on the risk profile of obesity-related complications, namely impaired tolerance of glucose, insulin resistance… Read more about this study
- Who is it for?
- Ages 6 to 14 years
- Conditions the study is for
- Obesity
- What is being tested?
- Vitamin D 1200 IU
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 200 participants
- Where
- 1 sitePoland
- Study dates
- Feb 2016to Feb 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 14 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- overweight (BMI between the 85th and 95th percentile) or obesity (BMI > 95th percentile), identified on the basis of anthropometric parameters
- blood concentration of 25(OH)D3 < 30 ng/ml
- written consent of legal guardians
Who cannot join
- Chronic conditions (asthma or allergies, inflammatory diseases of connective tissue, gastrointestinal disorders, diseases of kidneys and liver, disorders of bone metabolism)
- Contraindications to administration of vitamin D
- Administration of any preparation containing vitamin D, calcium, or steroid hormones during 3 months preceding the study
Trial locations and contacts
1 site in 1 country.
Poland1 site, 1 recruiting
- Recruiting
IUCCGdansk
Gdansk, Pomeranian Voivodeship, 80-210
Agnieszka Szlagatys, MD, PhD, 601622894, aga1@gumed.edu.pl
About this study
Official title: Long-term Effects of Vitamin D Supplementation in Vitamin D Deficient Obese Children During Integrated Weight-loss Program - a Double Blind Placebo Controlled Study
- Analyze the influence of vitamin D supplementation in obese children during weight-loss program on BMI, body composition and bone mineral density.
- Analyze the influence of vitamin D supplementation on the risk profile of obesity-related complications, namely impaired tolerance of glucose, insulin resistance, dyslipidemia and arterial hypertension, in obese children participating in weight-loss program.
- Analyze the prevalence of vitamin D deficiency among obese children.
- Analyze the risk factors of vitamin D deficiency in obese children (age, gender, pubertal status).
Read the detailed description
The study will be conducted as a continuation and development of "6-10-14 for Health" program. The first phase of the program, financed by the municipality of Gdansk, was conducted in 2011-2013. The program comprised of screening and survey conducted among all 6-, 10- and 14-year-old children attending primary and grammar schools. A total of 18 162 children (including 7 448 6-year olds, 6 720 10-year olds and 3 994 14-year olds) were examined. A group of children with risk factors of civilization-related diseases (overweight and obesity defined according to BMI percentile charts. was identified on the basis of the screening. This group included 2 798 (16.32%) children, among them 9.17% of 6-years of age, 19.30% of 10-years and 20.48% of 14-years). All these children were qualified to intervention and education program. A total of 1 627 children qualified on the basis of screening eventually took part in the first edition of the program.
A total of 4 meetings with participating children and their caregivers were scheduled during the 12-month-long education and intervention program: at enrollment, and 3, 6 and 12 months thereafter. The meetings had form of individual consultations with various specialists. The first visit included complex medical examination, discussion on a health status of a child, interpretation of laboratory findings, and consultations with dietician, psychologist and physical education specialist. After consulting all the specialists involved in the program, individual protocol of health intervention was developed for every child. The objectives of the intervention included modification of diet, increasing health activity level and strengthening of health-seeking behaviors of child's family members. Adherence to the protocol and achieved results were evaluated during follow-up meetings with the specialists, and constituted the basis for development of individualized intervention plans for subsequent months.
The preliminary evaluation of the program effects was conducted in the group of 300 participants. The average percentile of BMI at enrollment to the program and after 12 months of participation amounted to 92.96 and 88.83, respectively. Participation in the program was reflected by a significant decrease in BMI percentile (p=0.0001), as well as by a significant drop off in fat mass content measured by bioelectrical impedance, from 39.0% to 31.4% (p=0.0001).
On the basis of these findings, the municipality of Gdansk decided to support the program for 2014-2016.
The experiment will follow a pattern of double blind randomized study. The enrolled subjects will be randomly assigned to one of the two groups:
Group 1 - weight-loss program for 52 weeks + vitamin D 1200 (IU) daily for 26 weeks Group 2 - weight-loss program for 52 weeks +placebo daily for 26 weeks
Visit I: enrollment:
- medical history, physical examination
- interpretation of laboratory findings (the tests conducted during screening + concentration of vitamin D),
- anthropometric evaluation and analysis of body composition (bioimpedance method)
- consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention
- Kasch Pulse Recovery Test
- determination of hs-C-reactive protein, Interleukin 6, chemerin and adiponectin concentrations in blood samples obtained during screening
- informing parents about the objectives and protocol of the study
- obtaining written informed consent for participation in the study
- randomization to GROUP I or II
- densitometry (DXA) - within one week after enrollment
Visit II: after 13 weeks:
- medical history, physical examination
- anthropometric evaluation and analysis of body composition (bioimpedance method)
- consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention
Within a week prior to Visit III - obtaining blood (ca. 5 ml) for laboratory testing (complete blood count, lipid profile, hs-C-reactive protein, oral glucose tolerance test, insulin, Interleukin 6, adiponectin and chemerin concentrations
Visit III: after 26 weeks:
- medical history, physical examination
- interpretation of laboratory findings
- anthropometric evaluation and analysis of body composition (bioimpedance method)
- consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention
- obtaining blood for laboratory testing
- termination of active compound/placebo administration
Visit IV: after 52 weeks:
- medical history, physical examination
- anthropometric evaluation and analysis of body composition (bioimpedance method)
- consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention
- densitometry (DXA) - within one week after terminating the study
- Conditions
- Obesity
- Being tested
- Vitamin D 1200 IU, Placebo
- Keywords
- obesity, weight loss, vitamin D deficiency, body composition
- Medical subject headings
- Obesity, Weight Loss, Vitamin D Deficiency
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vitamin D 1200 IUDrug
Also called cholecalciferol
Vitamin D 1200 IU once a day for 26 weeks
PlaceboDrug
placebo once a day for 26 weeks
| Study group | Role | What they receive |
|---|---|---|
| Vitamin D 1200 IU | Experimental | Supplementation with vitamin D (1200 IU) once a day for 26 weeks Receives: Drug: Vitamin D 1200 IU |
| Placebo | Placebo comparator | Placebo once a day for 26 weeks Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Bone mineral density
Increase in bone mineral density during weight-loss program and vitamin D supplementation
Measured: 12 months
Secondary outcomes (7)
Blood level of vitamin D
Changes in blood level of vitamin D after supplementation
Measured: 12 months
Arterial blood pressure
Change in blood pressure afer weight-loss and vitamin D supplementation
Measured: 12 months
Lipid profile
Change of lipid profile after weight-loss and vitamin D supplementation
Measured: 12 months
Oral Glucose Tolerance Test
Change of biochemical parameters after weight-loss and vitamin D supplementation
Measured: 12 months
Chemerin
Change in chemerin level
Measured: 12 months
BMI (kg/m2)
Change of BMI during 12-months weight loss-program and supplementation of vitamin D
Measured: 12 months
Fat mass (kg)
Change in fat free mass during 12-months weight-loss programme and supplementation of vitamin D
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jul 2016 (estimated)
- Study startFeb 2016
- Primary completionFeb 2018 (estimated)
- Study completionFeb 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Clinical Centre, Gdansk
- Sponsor type
- University, hospital or other
- Collaborators
- Nutricia Foundation
- Responsible party
- Sponsor
- Investigators
- Agnieszka Szlagatys-Sidorkiewicz, MD, PhD, Principal investigator, University Clinical Centre, Gdansk
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02828228
- Sponsor's protocol ID
- 01/2016/UCK
- Status last verified
- Jul 2016
- First submitted
- 8 Jun 2016
- Last updated
- 11 Jul 2016
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Yes
Publications
Szlagatys-Sidorkiewicz A, Brzezinski M, Jankowska A, Metelska P, Slominska-Fraczek M, Socha P. Long-term effects of vitamin D supplementation in vitamin D deficient obese children participating in an integrated weight-loss programme (a double-blind placebo-controlled study) - rationale for the study design. BMC Pediatr. 2017 Apr 4;17(1):97. doi: 10.1186/s12887-017-0851-7.
PubMed 28376768
Study at a glance
From the registry record, last updated by the sponsor on 11 Jul 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long-term Effects of Vitamin D Supplementation in Vitamin D Deficient Obese Children During Integrated Weight-loss Program - a Double Blind Placebo Controlled Study
- ClinicalTrials.gov ID
- NCT02828228
- Acronym / sponsor ID
- 01/2016/UCK
- Conditions
- Obesity
- Keywords
- obesity, weight loss, vitamin D deficiency, body composition
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- University Clinical Centre, GdanskUniversity, hospital or other
- Collaborators
- Nutricia Foundation
- Study start
- Feb 2016
- Primary completion
- Feb 2018 (estimated)
- Study completion
- Feb 2019 (estimated)
- First posted
- 11 Jul 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- Analyze the influence of vitamin D supplementation in obese children during weight-loss program on BMI, body composition and bone mineral density.
- Analyze the influence of vitamin D supplementation on the risk profile of obesity-related complications, namely impaired tolerance of glucose, insulin resistance, dyslipidemia and arterial hypertension, in obese children participating in weight-loss program.
- Analyze the prevalence of vitamin D deficiency among obese children.
- Analyze the risk factors of vitamin D deficiency in obese children (age, gender, pubertal status).
Detailed description
The study will be conducted as a continuation and development of "6-10-14 for Health" program. The first phase of the program, financed by the municipality of Gdansk, was conducted in 2011-2013. The program comprised of screening and survey conducted among all 6-, 10- and 14-year-old children attending primary and grammar schools. A total of 18 162 children (including 7 448 6-year olds, 6 720 10-year olds and 3 994 14-year olds) were examined. A group of children with risk factors of civilization-related diseases (overweight and obesity defined according to BMI percentile charts. was identified on the basis of the screening. This group included 2 798 (16.32%) children, among them 9.17% of 6-years of age, 19.30% of 10-years and 20.48% of 14-years). All these children were qualified to intervention and education program. A total of 1 627 children qualified on the basis of screening eventually took part in the first edition of the program.
A total of 4 meetings with participating children and their caregivers were scheduled during the 12-month-long education and intervention program: at enrollment, and 3, 6 and 12 months thereafter. The meetings had form of individual consultations with various specialists. The first visit included complex medical examination, discussion on a health status of a child, interpretation of laboratory findings, and consultations with dietician, psychologist and physical education specialist. After consulting all the specialists involved in the program, individual protocol of health intervention was developed for every child. The objectives of the intervention included modification of diet, increasing health activity level and strengthening of health-seeking behaviors of child's family members. Adherence to the protocol and achieved results were evaluated during follow-up meetings with the specialists, and constituted the basis for development of individualized intervention plans for subsequent months.
The preliminary evaluation of the program effects was conducted in the group of 300 participants. The average percentile of BMI at enrollment to the program and after 12 months of participation amounted to 92.96 and 88.83, respectively. Participation in the program was reflected by a significant decrease in BMI percentile (p=0.0001), as well as by a significant drop off in fat mass content measured by bioelectrical impedance, from 39.0% to 31.4% (p=0.0001).
On the basis of these findings, the municipality of Gdansk decided to support the program for 2014-2016.
The experiment will follow a pattern of double blind randomized study. The enrolled subjects will be randomly assigned to one of the two groups:
Group 1 - weight-loss program for 52 weeks + vitamin D 1200 (IU) daily for 26 weeks Group 2 - weight-loss program for 52 weeks +placebo daily for 26 weeks
Visit I: enrollment:
- medical history, physical examination
- interpretation of laboratory findings (the tests conducted during screening + concentration of vitamin D),
- anthropometric evaluation and analysis of body composition (bioimpedance method)
- consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention
- Kasch Pulse Recovery Test
- determination of hs-C-reactive protein, Interleukin 6, chemerin and adiponectin concentrations in blood samples obtained during screening
- informing parents about the objectives and protocol of the study
- obtaining written informed consent for participation in the study
- randomization to GROUP I or II
- densitometry (DXA) - within one week after enrollment
Visit II: after 13 weeks:
- medical history, physical examination
- anthropometric evaluation and analysis of body composition (bioimpedance method)
- consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention
Within a week prior to Visit III - obtaining blood (ca. 5 ml) for laboratory testing (complete blood count, lipid profile, hs-C-reactive protein, oral glucose tolerance test, insulin, Interleukin 6, adiponectin and chemerin concentrations
Visit III: after 26 weeks:
- medical history, physical examination
- interpretation of laboratory findings
- anthropometric evaluation and analysis of body composition (bioimpedance method)
- consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention
- obtaining blood for laboratory testing
- termination of active compound/placebo administration
Visit IV: after 52 weeks:
- medical history, physical examination
- anthropometric evaluation and analysis of body composition (bioimpedance method)
- consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention
- densitometry (DXA) - within one week after terminating the study
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Vitamin D 1200 IU | Experimental | Drug: Vitamin D 1200 IUSupplementation with vitamin D (1200 IU) once a day for 26 weeks |
| Placebo | Placebo comparator | Drug: PlaceboPlacebo once a day for 26 weeks |
Who may qualify
- Ages
- 6 to 14 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- overweight (BMI between the 85th and 95th percentile) or obesity (BMI > 95th percentile), identified on the basis of anthropometric parameters
- blood concentration of 25(OH)D3 < 30 ng/ml
- written consent of legal guardians
Key exclusion criteria (3 listed)
- Chronic conditions (asthma or allergies, inflammatory diseases of connective tissue, gastrointestinal disorders, diseases of kidneys and liver, disorders of bone metabolism)
- Contraindications to administration of vitamin D
- Administration of any preparation containing vitamin D, calcium, or steroid hormones during 3 months preceding the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vitamin D 1200 IUAlso: cholecalciferolVitamin D 1200 IU once a day for 26 weeks | Drug | Vitamin D 1200 IU |
| Placeboplacebo once a day for 26 weeks | Drug | Placebo |
Primary outcome
Bone mineral density
Time frame: 12 months
Increase in bone mineral density during weight-loss program and vitamin D supplementation
7 secondary outcomes
Blood level of vitamin D
Time frame: 12 months
Arterial blood pressure
Time frame: 12 months
Lipid profile
Time frame: 12 months
Oral Glucose Tolerance Test
Time frame: 12 months
Chemerin
Time frame: 12 months
BMI (kg/m2)
Time frame: 12 months
Fat mass (kg)
Time frame: 12 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jul 2016.
- Derived from this study: PubMed 28376768Szlagatys-Sidorkiewicz A, Brzezinski M, Jankowska A, Metelska P, Slominska-Fraczek M, Socha P. Long-term effects of vitamin D supplementation in vitamin D deficient obese children participating in an integrated weight-loss programme (a double-blind placebo-controlled study) - rationale for the study design. BMC Pediatr. 2017 Apr 4;17(1):97. doi: 10.1186/s12887-017-0851-7.
- Individual participant dataSharing planned: Yes
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Agnieszka Szlagatys-Sidorkiewicz, MD, PhD principal investigator
University Clinical Centre, Gdansk
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Vitamin D 1200 IU in people with Obesity, run by University Clinical Centre, Gdansk at 1 site in Poland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 11 Jul 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Magdalena Słominska-Frączek, MD, (694844420, fraczek@gumed.edu.pl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Bone mineral density (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02828228, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2016.